Exicure, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
XCUR Nasdaq 2830 www.exicuretx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Exicure, Inc.

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement - Jun 10th, 2026 2:01 pm
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - Jun 1st, 2026 2:00 pm
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - Apr 22nd, 2026 5:54 pm
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - Apr 2nd, 2026 2:01 pm
Exicure, Inc. Reports Full Year 2025 Financial Results - Mar 25th, 2026 2:18 pm
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - Feb 5th, 2026 5:00 am
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - Jan 21st, 2026 5:00 am
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting - Dec 8th, 2025 2:30 pm
Exicure, Inc. Reports Third Quarter 2025 Financial Results - Nov 7th, 2025 2:00 pm
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting - Nov 3rd, 2025 7:00 am
Exicure Highlights Recent Achievements and Near-term Strategic Priorities - Oct 6th, 2025 5:00 am
Exicure, Inc. Reports Second Quarter 2025 Financial Results - Aug 8th, 2025 2:01 pm
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Aug 4th, 2025 2:37 pm
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Aug 1st, 2025 2:01 pm